Sponsored

MediKane tapping opportunities in diversified markets with Food-as-Medicine products - Kalkine Media

September 30, 2022 05:03 PM AEST | By Aditi Sarkar
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • MediKane has a portfolio of plant-based natural food products with scientific and clinical evidence to improve health.
  • The company targets diversified market segments including the medical, health, ingredients, animal health and white label space.
  • For these five separate markets, the company uses the same technology and supply chain.
  • Each market is global and growing faster than population growth.

Spending nearly a decade building the foundations to take its Australian innovations global, MediKane has witnessed its client base expand to include a diverse set of market segments.

The Australia-based company has been catering to the needs of plant-based treatments, also called Food-as-Medicine products, targeting several global chronic health conditions. The company has a portfolio of plant-based natural food products, backed by scientific and clinical evidence that they improve health. 

Historically, MediKane has focused on two market areas, aiding people in managing their blood sugar levels and acute constipation caused by opioid analgesic painkillers in hospital surgeries.

The company now targets diversified market segments, covering the medical, health, ingredients, animal health and white label space.

Let us graze through the market segments wherein MediKane offers or is ready to launch its range of reliable and innovative Food-as-Medicine products.

Health

Obesity, weight gain, lifestyle changes, and food choices have dramatically increased the number of people with high blood sugar levels (BSLs). In Australia, one person develops diabetes every five minutes. There is no superpower drug for this disease, and the main emphasis is on managing lifestyle and diet choices.

In such a scenario, MediKane’s flagship product NutriKane D is well placed to tap the emerging BSL space. It has demonstrated a positive impact on high BSLs in clinical trials.

As a food product, NutriKane D has been given a green signal for claims by the Food Standards Australia New Zealand (FSANZ) regarding the management of BSLs.

MediKane’s major market areas for NutriKane D are the US, UK, and Asia.

Learn about all MediKane products

Medical

Under the medical segment, the company majorly targets private and public hospitals. Opioid Induced Constipation (OIC) is a common problem due to the prolonged use of opioid drugs, prescribed for pain management in patients after surgery.

However, OIC increases patient discomfort. It also increases the cumulative cost of treatment and hospital waiting times.

MediKane is actively pursuing major areas for using NutriKane R with a focus on the Australian and US markets. In these countries, private hospitals and facilities have an incentive for optimised cost management by improving the availability of beds.

NutriKane R, already on the market, is designed for people who want improved bowel health and regularity and looking for natural medications, plus those in hospitals or aged care facilities with constipation.

Ingredients

MediKane also supplies plant-based products to food processors through its division, MediKane Ingredients. The food processors use these ingredients to make final products. The target segments include processed meat producers, health food manufacturers and bakeries.

MediKane suggests that this global market segment of US$5.4 billion is expected to grow at a CAGR of 12.9% during 2020-2026.

MediKane has strong distribution networks in the ingredients market in Australia, Europe and the USA.

Animal health

MediKane’s products from the NutriKane range work the same way in animals as in humans. As of 2019, the global animal health market is worth US$637 million and is growing at an annual rate of 6.4 %, as per the company. The market growth is mainly backed by socioeconomic factors and the humanisation of pets.

MediKane has created a joint venture to tap into this segment. The venture is called PetKane and several of the key personnel involved have already been conducting scientific tests for the past five years on dogs, cats, and horses, with NutriKane proving its efficiency. PetKane is developing  relationships with a global network of veterinarians and other animal lovers.

PetKane is now selling, under the brand name Chica, with animal products in powder form.

White Label

Owing to the quality of ingredients offered, MediKane has established a growing White Label business. The company believes its new and unique product offerings have the potential for outstanding growth.

The company expects the human nutrition market to grow at a robust pace over the coming years due to increasing consumer awareness about healthy living and eating benefits.

Backed by a global presence and innovative set of product offerings, MediKane is committed to becoming a major provider of safe plant-based ‘Food-as-Medicine’ products for the treatment of specific acute and chronic health problems. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.